Aytu BioPharma Reports Strong Q3 2025 Financial Performance

Aytu BioPharma, Inc., a specialty healthcare company listed on the Nasdaq, has announced its fiscal 2025 third-quarter operational and financial results, showcasing significant growth and positive financial metrics. The company, which focuses on developing and commercializing products for sexual dysfunction disorders, urological cancer, urinary tract infections, and male infertility, reported a net income of $4.0 million, translating to $0.65 per share on a basic basis and $0.21 per share on a diluted basis.

Key Financial Highlights

  • Revenue Growth: Total net revenue for the quarter was $18.5 million, marking a 32% increase year-over-year from $14.0 million in the same quarter of fiscal 2024. This growth was primarily driven by the company’s ADHD Portfolio, which includes Adzenys XR-ODT® and Cotempla XR-ODT®, with net revenue increasing by 25% to $15.4 million.

  • Adjusted EBITDA: The company reported an Adjusted EBITDA of $3.9 million for the quarter.

  • Earnings Per Share: Aytu BioPharma’s non-GAAP earnings per share (EPS) of $0.65 exceeded expectations by $4.76 million.

Conference Call and Webcast

Aytu BioPharma is set to host a conference call and webcast today, May 14, 2025, at 4:30 p.m. Eastern time, to discuss these results in detail. The event will provide further insights into the company’s performance and strategic direction.

Market Outlook

Despite the strong quarterly performance, analysts have mixed expectations for the upcoming quarters. One analyst anticipates a potential earnings per share of $0.720 for the current fiscal year, a significant improvement from the previous year’s -$2.860 per share. However, the same analyst predicts a revenue decline of 23.62% to $13.7 million for the quarter ending March 31, 2025, compared to $18.0 million in the prior year. For the full fiscal year, revenue is projected at $67.1 million, down from $81.0 million in the previous year.

Company Overview

Aytu BioPharma, Inc. operates in the Health Care sector, specifically within the Pharmaceuticals industry. The company is headquartered in Denver, CO, and serves a global customer base. As of May 12, 2025, Aytu BioPharma’s stock closed at $1.31, with a market capitalization of $8.24 million. The company’s stock has experienced a 52-week range, with a high of $3.24 on May 23, 2024, and a low of $0.95 on April 6, 2025.

For more information, visit Aytu BioPharma’s official website at www.aytubio.com .